Aman Mehta

About

In August, Torrent Pharmaceuticals, the flagship company of the ₹45,000-crore Torrent Group, will have a new MD—the 34-year-old Aman Mehta, the eldest son of chairman Samir Mehta, who built Torrent into one of India’s biggest business houses along with his elder brother and chairman emeritus Sudhir Mehta. When Aman joined Torrent Pharma in 2018 as general manager with strategy responsibilities, the domestic business was worth ₹3,000–4,000 crore a year. For the next two years, Aman focussed on the integration and strategic growth plan of Unichem Laboratories’ branded business in India and Nepal, which Torrent bought in 2017 for ₹3,600 crore. In August 2022, Aman was promoted as director, Torrent Pharmaceuticals. In June, Torrent Pharma announced the acquisition of a controlling stake in JB Chemicals and Pharmaceuticals from global investment firm KKR, in a deal valued at ₹18,000–19,000 crore (including an open offer). The move will help Torrent break into the top five domestic pharma firms. From 2018, Torrent Pharma’s domestic business, which contributes 55% of its total revenues, saw a 15%-plus CAGR to reach over ₹6,500 crore in FY25. “Today we are the seventh-largest domestic pharma company with the highest growth rate among the Top 10. Our vision is to become the third-largest within the next three to five years,” says Aman. Revenues rose 7% YoY to ₹11,516 crore in FY25. Net profit was up 15% to ₹1,911 crore. The four areas—cardiac care, gastro, dermatology, and vitamins & minerals—remain the big focus. The firm is looking for mid-to-large acquisitions in India and Brazil, says Aman. He is also a key figure in strategy-making at the group level, which includes its foray into sports by acquiring IPL team Gujarat Titans and diversifications into hospitals and diagnostics.